{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:46:23Z","timestamp":1778496383271,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["106-2314-B-002-051-MY3"],"award-info":[{"award-number":["106-2314-B-002-051-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["106-2314-B-002-229-MY3"],"award-info":[{"award-number":["106-2314-B-002-229-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["109-2314-B-002-102"],"award-info":[{"award-number":["109-2314-B-002-102"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["109-2314-B-002-229-MY3"],"award-info":[{"award-number":["109-2314-B-002-229-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["111-2628-E007-MY3"],"award-info":[{"award-number":["111-2628-E007-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["112-2628-B-110-004-MY3"],"award-info":[{"award-number":["112-2628-B-110-004-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["112-2221-E-002-115"],"award-info":[{"award-number":["112-2221-E-002-115"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>As of 2020, hepatocellular carcinoma (HCC), a form of liver cancer, stood as the third most prominent contributor to global cancer-related mortality. Combining immune checkpoint inhibitors (ICI) with other therapies has shown promising results for treating unresectable HCC, offering new opportunities. Recombinant adeno-associated viral type 2 (AAV2) virotherapy has been approved for clinical use but it efficacy is stifled through systemic administration. On the other hand, iron oxide nanoparticles (ION) can be cleared via the liver and enhance macrophage polarization, promoting infiltration of CD8<jats:sup>+<\/jats:sup> T cells and creating a more favorable tumor microenvironment for immunotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To enhance the efficacy of virotherapy and promote macrophage polarization towards the M1-type in the liver, ION-AAV2 were prepared through the coupling of ION-carboxyl and AAV2-amine using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC)\/N-hydroxysulfosuccinimide (Sulfo-NHS). Efficacy after systemic delivery of ION-AAV2 in an orthotopic HCC model was evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After 28\u00a0days, the tumor weight in mice treated with ION-AAV2 was significantly reduced by 0.56-fold compared to the control group. The ION-AAV2 treatment led to an approximate 1.80-fold increase in the level of tumor associated M1-type macrophages, while the number of M2-type macrophages was reduced by 0.88-fold. Moreover, a proinflammatory response increased the population of tumor-infiltrating CD8<jats:sup>+<\/jats:sup> T cells in the ION-AAV2 group. This transformation converted cold tumors into hot tumors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings suggest that the conjugation of ION with AAV2 could be utilized in virotherapy while simultaneously exploiting macrophage-modulating cancer immunotherapies to effectively suppress HCC growth.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12929-023-00989-1","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T05:42:40Z","timestamp":1704174160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Nano-modified viruses prime the tumor microenvironment and promote the photodynamic virotherapy in liver cancer"],"prefix":"10.1186","volume":"31","author":[{"given":"Da-Liang","family":"Ou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Xian","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan M.","family":"Kempson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan-Chyr","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1299-7202","authenticated-orcid":false,"given":"S.-Ja","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"key":"989_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"989_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.","journal-title":"Nat Rev Dis Primers"},{"key":"989_CR3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","volume":"5","author":"A Huang","year":"2020","unstructured":"Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5:146.","journal-title":"Signal Transduct Target Ther"},{"key":"989_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","volume":"23","author":"JD Twomey","year":"2021","unstructured":"Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J. 2021;23:39.","journal-title":"AAPS J"},{"key":"989_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","volume":"18","author":"B Sangro","year":"2021","unstructured":"Sangro B, Sarobe P, Herv\u00e1s-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18:525\u201343.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"989_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.36128","volume":"4","author":"AA J\u00e1come","year":"2021","unstructured":"J\u00e1come AA, Castro ACG, Vasconcelos JPS, Silva MHCR, Lessa MAO, Moraes ED, Andrade AC, Lima FMT, Farias JPF, Gil RA, et al. Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: a meta-analysis. JAMA Netw Open. 2021;4: e2136128.","journal-title":"JAMA Netw Open"},{"key":"989_CR7","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13045-019-0817-3","volume":"12","author":"Z Zhao","year":"2019","unstructured":"Zhao Z, Zheng L, Chen W, Weng W, Song J, Ji J. Delivery strategies of cancer immunotherapy: recent advances and future perspectives. J Hematol Oncol. 2019;12:126.","journal-title":"J Hematol Oncol"},{"key":"989_CR8","doi-asserted-by":"publisher","first-page":"2100048","DOI":"10.1002\/adtp.202100048","volume":"4","author":"DL Ou","year":"2021","unstructured":"Ou DL, Tseng SJ, Kempson IM, Hsu CL, Yang PC, Liao ZX. Enhanced targeting and immune activation of tumor microenvironment by nanomodified anti-PD1 in liver cancer. Adv Ther. 2021;4:2100048.","journal-title":"Adv Ther"},{"key":"989_CR9","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862\u201373.","journal-title":"J Hepatol"},{"key":"989_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","volume":"21","author":"C Li","year":"2020","unstructured":"Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet. 2020;21:255\u201372.","journal-title":"Nat Rev Genet"},{"key":"989_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/d41573-021-00017-7","volume":"20","author":"DA Kuzmin","year":"2021","unstructured":"Kuzmin DA, Shutova MV, Johnston NR, Smith OP, Fedorin VV, Kukushkin YS, van der Loo JCM, Johnstone EC. The clinical landscape for AAV gene therapies. Nat Rev Drug Discov. 2021;20:173\u20134.","journal-title":"Nat Rev Drug Discov"},{"key":"989_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108521","volume":"250","author":"ZX Liao","year":"2023","unstructured":"Liao ZX, Hsu Sh, Tang SC, Kempson I, Yang PC, Tseng SJ. Potential targeting of the tumor microenvironment to improve cancer virotherapy. Pharmacol Ther. 2023;250: 108521.","journal-title":"Pharmacol Ther"},{"key":"989_CR13","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/d41573-023-00103-y","volume":"22","author":"A Mullard","year":"2023","unstructured":"Mullard A. FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections. Nat Rev Drug Discov. 2023;22:610.","journal-title":"Nat Rev Drug Discov"},{"key":"989_CR14","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/526622a","volume":"526","author":"H Ledford","year":"2015","unstructured":"Ledford H. Cancer-fighting viruses win approval. Nature. 2015;526:622\u20133.","journal-title":"Nature"},{"key":"989_CR15","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358\u201378.","journal-title":"Nat Rev Drug Discov"},{"key":"989_CR16","doi-asserted-by":"publisher","first-page":"10339","DOI":"10.1021\/acsnano.6b06051","volume":"10","author":"SJ Tseng","year":"2016","unstructured":"Tseng SJ, Huang KY, Kempson IM, Kao SH, Liu MC, Yang SC, Liao ZX, Yang PC. Remote control of light-triggered virotherapy. ACS Nano. 2016;10:10339\u201346.","journal-title":"ACS Nano"},{"key":"989_CR17","doi-asserted-by":"publisher","first-page":"9894","DOI":"10.1021\/acsnano.8b02813","volume":"12","author":"SJ Tseng","year":"2018","unstructured":"Tseng SJ, Kempson IM, Huang KY, Li HJ, Fa YC, Ho YC, Liao ZX, Yang PC. Targeting tumor microenvironment by bioreduction-activated nanoparticles for light-triggered virotherapy. ACS Nano. 2018;12:9894\u2013902.","journal-title":"ACS Nano"},{"key":"989_CR18","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.addr.2019.01.005","volume":"138","author":"SM Dadfar","year":"2019","unstructured":"Dadfar SM, Roemhild K, Drude NI, von Stillfried S, Kn\u00fcchel R, Kiessling F, Lammers T. Iron oxide nanoparticles: diagnostic, therapeutic and theranostic applications. Adv Drug Deliv Rev. 2019;138:302\u201325.","journal-title":"Adv Drug Deliv Rev"},{"key":"989_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12929-019-0568-z","volume":"26","author":"Y Chen","year":"2019","unstructured":"Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019;26:78.","journal-title":"J Biomed Sci"},{"key":"989_CR20","doi-asserted-by":"publisher","first-page":"6122","DOI":"10.1021\/jacs.8b10904","volume":"141","author":"Z Gu","year":"2019","unstructured":"Gu Z, Liu T, Tang J, Yang Y, Song H, Tuong ZK, Fu J, Yu C. Mechanism of iron oxide-induced macrophage activation: the impact of composition and the underlying signaling pathway. J Am Chem Soc. 2019;141:6122\u20136.","journal-title":"J Am Chem Soc"},{"key":"989_CR21","doi-asserted-by":"publisher","first-page":"35906","DOI":"10.1021\/acsami.3c05555","volume":"15","author":"Y Portilla","year":"2023","unstructured":"Portilla Y, Mulens-Arias V, Daviu N, Paradela A, P\u00e9rez-Yag\u00fce S, Barber DF. Interaction of iron oxide nanoparticles with macrophages is influenced distinctly by \u201cself\u201d and \u201cnon-self\u201d biological identities. ACS Appl Mater Interfaces. 2023;15:35906\u201326.","journal-title":"ACS Appl Mater Interfaces"},{"key":"989_CR22","doi-asserted-by":"publisher","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","volume":"115","author":"E Peranzoni","year":"2018","unstructured":"Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C, Bercovici N, Gu\u00e9rin M, Biton J, Ouakrim H, et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc Natl Acad Sci U S A. 2018;115:E4041\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"989_CR23","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.7150\/thno.58390","volume":"11","author":"YT Liu","year":"2021","unstructured":"Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11:5365\u201386.","journal-title":"Theranostics"},{"key":"989_CR24","doi-asserted-by":"publisher","first-page":"6456","DOI":"10.1038\/ncomms7456","volume":"6","author":"SJ Tseng","year":"2015","unstructured":"Tseng SJ, Liao ZX, Kao SH, Zeng YF, Huang KY, Li HJ, Yang CL, Deng YF, Huang CF, Yang SC, et al. Highly specific in vivo gene delivery for p53-mediated apoptosis and genetic photodynamic therapies of tumour. Nat Commun. 2015;6:6456.","journal-title":"Nat Commun"},{"key":"989_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2022.101582","volume":"46","author":"SJ Tseng","year":"2022","unstructured":"Tseng SJ, Kempson IM, Liao ZX, Ho YC, Yang PC. An acid degradable, lactate oxidizing nanoparticle formulation for non-small cell lung cancer virotherapy. Nano Today. 2022;46: 101582.","journal-title":"Nano Today"},{"key":"989_CR26","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1021\/acs.bioconjchem.9b00618","volume":"30","author":"Z-X Liao","year":"2019","unstructured":"Liao Z-X, Fa YC, Kempson IM, Tseng SJ. Repolarization of M2 to M1 macrophages triggered by lactate oxidase released from methylcellulose hydrogel. Bioconjug Chem. 2019;30:2697\u2013702.","journal-title":"Bioconjug Chem"},{"key":"989_CR27","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature12875","volume":"506","author":"L Lisowski","year":"2014","unstructured":"Lisowski L, Dane AP, Chu K, Zhang Y, Cunningham SC, Wilson EM, Nygaard S, Grompe M, Alexander IE, Kay MA. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature. 2014;506:382\u20136.","journal-title":"Nature"},{"key":"989_CR28","doi-asserted-by":"publisher","first-page":"13346","DOI":"10.3390\/ijms222413346","volume":"22","author":"ZX Liao","year":"2021","unstructured":"Liao ZX, Ou DL, Hsieh MJ, Hsieh CC. Synergistic effect of repolarization of M2 to M1 macrophages induced by iron oxide nanoparticles combined with lactate oxidase. Int J Mol Sci. 2021;22:13346.","journal-title":"Int J Mol Sci"},{"key":"989_CR29","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1016\/j.drudis.2021.07.014","volume":"26","author":"ZX Liao","year":"2021","unstructured":"Liao ZX, Kempson IM, Hsieh CC, Tseng SJ, Yang PC. Potential therapeutics using tumor-secreted lactate in nonsmall cell lung cancer. Drug Discov Today. 2021;26:2508\u201314.","journal-title":"Drug Discov Today"},{"key":"989_CR30","doi-asserted-by":"publisher","first-page":"24020","DOI":"10.1021\/acsomega.2c03213","volume":"7","author":"CC Hsieh","year":"2022","unstructured":"Hsieh CC, Hsieh MJ, Wang YH, Liao ZX. Macrophage distribution affected by virus-encoded granulocyte macrophage colony stimulating factor combined with lactate oxidase. ACS Omega. 2022;7:24020\u20136.","journal-title":"ACS Omega"},{"key":"989_CR31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov H, Orhan A, Christensen JP, G\u00f6genur I. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br J Cancer. 2021;124:359\u201367.","journal-title":"Br J Cancer"},{"key":"989_CR32","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ymthe.2023.01.010","volume":"31","author":"M Schulz","year":"2023","unstructured":"Schulz M, Levy DI, Petropoulos CJ, Bashirians G, Winburn I, Mahn M, Somanathan S, Cheng SH, Byrne BJ. Binding and neutralizing anti-AAV antibodies: detection and implications for rAAV-mediated gene therapy. Mol Ther. 2023;31:616\u201330.","journal-title":"Mol Ther"},{"key":"989_CR33","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.2217\/nnm-2021-0255","volume":"16","author":"CS Nascimento","year":"2021","unstructured":"Nascimento CS, Alves \u00c9AR, de Melo CP, Corr\u00eaa-Oliveira R, Calzavara-Silva CE. Immunotherapy for cancer: effects of iron oxide nanoparticles on polarization of tumor-associated macrophages. Nanomed. 2021;16:2633\u201350.","journal-title":"Nanomed"},{"key":"989_CR34","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1039\/D1NH00179E","volume":"6","author":"S Chung","year":"2021","unstructured":"Chung S, Revia RA, Zhang M. Iron oxide nanoparticles for immune cell labeling and cancer immunotherapy. Nanoscale Horiz. 2021;6:696\u2013717.","journal-title":"Nanoscale Horiz"},{"key":"989_CR35","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.2741\/4848","volume":"25","author":"D Fokam","year":"2020","unstructured":"Fokam D, Hoskin D. Instrumental role for reactive oxygen species in the inflammatory response. Front Biosci. 2020;25:1110\u20139.","journal-title":"Front Biosci"},{"key":"989_CR36","doi-asserted-by":"publisher","first-page":"8459402","DOI":"10.1155\/2017\/8459402","volume":"2017","author":"I Lorenzen","year":"2017","unstructured":"Lorenzen I, Mullen L, Bekeschus S, Hanschmann EM. Redox regulation of inflammatory processes is enzymatically controlled. Oxid Med Cell Longev. 2017;2017:8459402.","journal-title":"Oxid Med Cell Longev"},{"key":"989_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.freeradbiomed.2019.12.022","volume":"157","author":"L Mullen","year":"2020","unstructured":"Mullen L, Mengozzi M, Hanschmann EM, Alberts B, Ghezzi P. How the redox state regulates immunity. Free Radic Biol Med. 2020;157:3\u201314.","journal-title":"Free Radic Biol Med"},{"key":"989_CR38","doi-asserted-by":"crossref","unstructured":"Tyurin VA, Balasubramanian K, Winnica D, Tyurina YY, Vikulina AS, He RR, Kapralov AA, Macphee CH, Kagan VE. Oxidatively modified phosphatidylserines on the surface of apoptotic cells are essential phagocytic \u201ceat-me\u201d signals: cleavage and inhibition of phagocytosis by Lp-PLA2. Cell Death Differ. 2014;21:825\u201335.","DOI":"10.1038\/cdd.2014.1"},{"key":"989_CR39","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","volume":"6","author":"Z Duan","year":"2021","unstructured":"Duan Z, Luo Y. Targeting macrophages in cancer immunotherapy. Signal Transduct Target Ther. 2021;6:127.","journal-title":"Signal Transduct Target Ther"},{"key":"989_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001341","volume":"9","author":"C Li","year":"2021","unstructured":"Li C, Xu X, Wei S, Jiang P, Xue L, Wang J. Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer. J Immunother Cancer. 2021;9: e001341.","journal-title":"J Immunother Cancer"},{"key":"989_CR41","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1016\/j.apsb.2021.10.019","volume":"12","author":"J Zhao","year":"2022","unstructured":"Zhao J, Huang H, Zhao J, Xiong X, Zheng S, Wei X, Zhou S. A hybrid bacterium with tumor-associated macrophage polarization for enhanced photothermal-immunotherapy. Acta Pharm Sin B. 2022;12:2683\u201394.","journal-title":"Acta Pharm Sin B"},{"key":"989_CR42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/ni.3324","volume":"17","author":"F Ginhoux","year":"2016","unstructured":"Ginhoux F, Schultze JL, Murray PJ, Ochando J, Biswas SK. New insights into the multidimensional concept of macrophage ontogeny, activation and function. Nat Immunol. 2016;17:34\u201340.","journal-title":"Nat Immunol"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-023-00989-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12929-023-00989-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-023-00989-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T16:17:09Z","timestamp":1704212229000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbiomedsci.biomedcentral.com\/articles\/10.1186\/s12929-023-00989-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["989"],"URL":"https:\/\/doi.org\/10.1186\/s12929-023-00989-1","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"23 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal studies were conducted in accordance with the Animal Use Protocol (IACUC-20160366) approved by the Institutional Animal Care and Use Committee of the College of Medicine, National Taiwan University. All authors approved and directly participated in the planning, execution of the experiments, and analysis of the data presented herein.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}